Drug Trial Radar · NCT07207057
Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Sep 12, 2025
Primary completion
May 2031
Study completion Jul 31, 2031
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cure Parkinson's; Parkinson's UK; National Institute for Health Research, United Kingdom; John Black Charitable Foundation; Medical Research Council; Newcastle University; Van Andel Research Institute; Michael J. Fox Foundation for Parkinson's Research; Gatsby Foundation
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Parkinson's disease (PD) is currently the fastest-growing neurological condition globally. It is projected to affect 172,000 people in the UK by 2030,with the current annual cost to the country being \~£3.6 billion. The disease progressively impairs physical abilities, leading to increased disability, falls, and difficulties with speech, swallowing, mood, thinking, and memory. While existing treatments can alleviate some symptoms, their effectiveness diminishes over time, and they can cause severe side effects. This trial uses a Multi-Arm,Multi-Stage (MAMS) design where multiple treatments are tested simultaneously in separate groups, called "arms." Each treatment is compared against a placebo, a dummy treatment with no active ingredients, to evaluate its effectiveness and safety. Throughout the trial, each treatment undergoes periodic reviews, known as interim analyses, to assess its safety and potential benefits. If a treatment shows promise, it continues in the trial until a final assessment determines its overall effectiveness. Treatments that do not show positive results are discontinued and replaced with new candidates. This approach reduces the number of participants needed to obtain reliable results and is more cost-effective and faster than conducting separate trials for each treatment. The treatments selected for this trial were chosen based on careful consideration of existing evidence regarding their safety and effectiveness. To choose the treatments we want to test, we carefully considered evidence for safety and effectiveness. The trial will start with two treatment arms (telmisartan and terazosin) and one placebo arm, with a third treatment arm added after one year. We can identify new treatments to add to the trial each year. Participants will be followed up for up to 36 months. After an in-person screening visit, all remaining visits at 3 months,6 months and then every 6 months after, for a total of up to 36 months can be completed remotely. The visits will include questionnaires, assessment of Parkinson's symptoms and discussions about any side effects. Participants will informed of trial progress. Results will be shared via the trial website and published in a medical journal.
Conditions
- Parkinsons Disease (PD)
Interventions
PlaceboDrug
An over-encapsulated placebo capsule taken once daily to match the treatment arms following a 5-week titration phase.
TelmisartanDrug
Over-encapsulated telmisartan 40mg per day for 36 months (plus their usual SoC) following a 5-week titration phase. Titration phase for telmisartan: Week 1-3: one 20 mg capsule per day; Week 4-5: one 40 mg capsule per day
Terazosin (Hytrin)Drug
Over-encapsulated terazosin 5mg per day for 36 months (plus their usual SoC) following a 5-week titration phase. Titration phase for terazosin: Week 1: one 1 mg capsule per day; Week 2: one 2 mg capsule per day; Week 3: one 3 mg capsule per day; Week 4: one 4 mg capsule per day; Week 5: one 5 mg capsule per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I and II combinedTime frame: baseline, week 13, week 26, week 52, week 78, week 104, week 130, week 156 (end of study visit) or early termination and week 165
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UCLH
London, United Kingdom · Recruiting
Clinical Ageing Research Unit
Newcastle, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.